First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Werewolf Therapeutics, Inc.

    HOWL · 4 developments mapped · last assessed 2026-08-21

    Market Ontology has mapped 4 macro, policy, and market developments to Werewolf Therapeutics, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for HOWL yet, so no modelled value is shown. The HOWL valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run HOWL on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for HOWL. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M)

      Direct acquisition of another company, resulting in a change of corporate identity and ticker symbol, and potential dilution for existing shareholders.

      · Moves future growth rates, synergy realization, cost of capital

    What changed, by assumption

    Future growth rates
    • 2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M)
    • 2026-08-21Werewolf Therapeutics, Inc. Files Business Combination Communication
    Future growth rates for the combined entity
    • 2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M)
    Future cash flows (due to increased r&d/operational capacity)
    • 2026-08-21Werewolf Therapeutics, Inc. Follow-On — $150M

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-21Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-21Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-08-21Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-21Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-21RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70
    2026-07-31Valuation multipleBullishTarget re-rates to bid premium until close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M)mixed1-3m0.80
    2026-08-21Werewolf Therapeutics, Inc. Files Business Combination Communicationmixed1-3m0.70
    2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M)mixed1-3m0.70
    2026-08-21Werewolf Therapeutics, Inc. Follow-On — $150Mmixed1-3m0.70